Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
03. November 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
20. März 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic AXS-05 and placebo arms fully enrolled with estimated completion rate of...
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
29. Oktober 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
10. Dezember 2018 07:00 ET
|
Axsome Therapeutics, Inc.
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation IDMC recommends no further enrollment to single-agent bupropion arm NEW YORK, Dec. 10, 2018 ...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
18. Oktober 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
08. August 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
12. März 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation
17. Juli 2017 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in the ADVANCE-1 study Agitation reported in nearly 50% of patients with Alzheimer’s disease FDA Fast Track designation previously received for AXS-05 for Alzheimer’s disease...